论文部分内容阅读
目的 评价采用美国BardMagnum活检装置 (NoMG15 2 2 )及与之配套的BardMagnum活检针行透视或CT定位下经皮肺穿刺活检诊断肺周围性病变的临床价值。方法 根据病灶的位置、性状及距胸壁的距离 ,选择定位方法。其中 6 4例采用透视下经皮肺穿刺活检 ;2 9例 (包括透视定位穿刺不成功者 5例 )采用CT定位下经皮肺穿刺活检。结果 两种定位方法穿刺取材的成功率分别为 92 .2 % ,96 .5 % ;诊断阳性率分别为 87.5 % ,93.1% ;并发症的发生率分别为 12 .5 %和 7%。两种方法无显著性差异。结论 采用美国BardMagnum活检装置 (NoMG15 2 2 )及与之配套的BardMagnum活检针行透视或CT定位下经皮肺穿刺活检诊断肺周围性病变是较为理想的安全的方法
Objective To evaluate the clinical value of percutaneous pulmonary biopsy in the diagnosis of peripheral pulmonary disease by fluoroscopy with BardMagnum biopsy device (NoMG15 2 2) and its accompanying Bard Magnin biopsy needle. Methods According to the location of lesions, traits and the distance from the chest wall, select the positioning method. Among them, 64 cases underwent percutaneous pulmonary biopsy under fluoroscopy; 29 cases (including 5 cases unsuccessfully under fluoroscopy) were percutaneously punctured with CT. Results The successful rates of the two methods were 92.2% and 96.5%, respectively. The positive rates of diagnosis were 87.5% and 93.1% respectively. The incidences of complications were 12.5% and 7% respectively. No significant difference between the two methods. Conclusion Percutaneous pulmonary biopsy under fluoroscopic or CT biopsy using the BardMagnum biopsy device (NoMG152 2) and its accompanying Bard Magnin biopsy needle is an ideal and safe method